Segall Bryant & Hamill LLC Has $41.34 Million Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Segall Bryant & Hamill LLC lowered its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 3.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 297,675 shares of the medical instruments supplier's stock after selling 9,142 shares during the quarter. ICU Medical accounts for approximately 0.6% of Segall Bryant & Hamill LLC's holdings, making the stock its 26th biggest holding. Segall Bryant & Hamill LLC owned 1.21% of ICU Medical worth $41,335,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ICUI. Norges Bank purchased a new stake in ICU Medical during the 4th quarter worth about $40,151,000. GAMMA Investing LLC increased its position in ICU Medical by 17,559.7% during the 1st quarter. GAMMA Investing LLC now owns 99,424 shares of the medical instruments supplier's stock worth $138,060,000 after purchasing an additional 98,861 shares in the last quarter. Point72 Asset Management L.P. increased its position in ICU Medical by 63.2% during the 4th quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier's stock worth $38,069,000 after purchasing an additional 95,030 shares in the last quarter. Dimensional Fund Advisors LP increased its position in ICU Medical by 18.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock worth $83,788,000 after purchasing an additional 82,982 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in ICU Medical during the 4th quarter worth about $10,003,000. Hedge funds and other institutional investors own 96.10% of the company's stock.

Insiders Place Their Bets

In other ICU Medical news, Director Elisha W. Finney sold 600 shares of ICU Medical stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $138.92, for a total transaction of $83,352.00. Following the sale, the director directly owned 3,252 shares in the company, valued at $451,767.84. The trade was a 15.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Christian B. Voigtlander sold 4,985 shares of ICU Medical stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total value of $640,572.50. Following the sale, the chief operating officer owned 6,088 shares in the company, valued at $782,308. This represents a 45.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,097 shares of company stock valued at $4,860,156 over the last 90 days. 1.50% of the stock is owned by company insiders.

ICU Medical Trading Down 1.8%

Shares of NASDAQ ICUI traded down $2.25 during midday trading on Friday, hitting $122.47. The stock had a trading volume of 139,373 shares, compared to its average volume of 255,900. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of -31.98 and a beta of 0.87. ICU Medical, Inc. has a 1-year low of $117.92 and a 1-year high of $196.26. The company has a quick ratio of 1.52, a current ratio of 2.59 and a debt-to-equity ratio of 0.75. The company has a fifty day moving average price of $132.57 and a 200 day moving average price of $143.98.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating the consensus estimate of $1.23 by $0.49. The business had revenue of $599.49 million for the quarter, compared to the consensus estimate of $574.15 million. ICU Medical had a positive return on equity of 6.75% and a negative net margin of 3.87%. The company's revenue was up 6.7% on a year-over-year basis. During the same period last year, the business posted $0.96 EPS. On average, analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Raymond James Financial decreased their price target on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a research note on Friday, May 9th. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday, May 18th. KeyCorp decreased their price target on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Finally, Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $192.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.